The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

Myeloid leukaemias are among the most aggressive blood cancers and have low survival rates. Today, leukaemia patients undergo genetic analysis to identify mutations and select the most appropriate ...

Early diagnosis of lung cancer is a critical priority in clinical practice. It may help reduce the rate of lung-cancer-related mortality, extend disease-free survival, and allow patients to live ...

Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.